Funding for Metyos for developing biowearable sensor and disease management platform

Led by Cenitz and joined by investors including KIMA Ventures, Advans Lab, and Bpifrance, the funding will support Metyos in developing its biowearable sensor and disease management platform.

Founded by CEO Alexandre Boulanger and CTO Olga Chashchina, Metyos aims to transform CKD management by providing continuous health monitoring through its technology.

Alexandre Boulanger, CEO and Co-founder of Metyos said: “Our mission at Metyos is to move healthcare away from reactive care towards proactive disease management. A healthcare future where millions of CKD patients are empowered to take control of their health, and where they can access life-saving early detection and personalised interventions. This funding, and the support and belief of the brilliant investors it brings with it, will help make this future a reality and help change the lives of so many patients and medical professionals worldwide.”

This platform, the company says, empowers both patients and healthcare professionals to make informed decisions in real-time, enhancing the effectiveness of treatments and improving patient outcomes.

CKD affects over 800 million people globally and is a significant contributor to healthcare costs. By enabling personalized interventions and early detection of symptoms, Metyos says it seeks to alleviate the burden of CKD on patients and healthcare systems. The company's wearable sensor monitors biomarkers linked to CKD, allowing for the timely adjustment of medications and dietary recommendations.

The funding will support Metyos in conducting clinical trials to further validate its technology and pursue regulatory clearance. Alexandre Boulanger expressed gratitude for the support from investors, emphasizing the company's commitment to proactive disease management. He highlighted the potential of Metyos' technology to transform healthcare by empowering patients and facilitating personalized care.

Frederic Picq at Cenitz praised Metyos' founding team and innovative approach to healthcare. He emphasized the company's potential to redefine CKD management and improve patient outcomes. Metyos invites individuals interested in contributing to its clinical trials to reach out through its website.

He said: "Our investment in Metyos was driven by its impressive founding team, a clear and growing market need, and the life-changing potential of its technology. Alex and Olga bring a blend of entrepreneurial spirit and technical expertise that is rare and invaluable in the medtech space.

“Their track record and passion for healthcare innovation are evident in the strides Metyos has already made. We see significant opportunity in Metyos not just because of its groundbreaking approach to CKD management, but because it represents the future of healthcare – a future where technology and the human experience come together to offer better, proactive care for all.”

Metyos' technology represents a significant step towards personalized medicine and proactive disease management. With the support of investors and the dedication of its founders, the company says it is poised to make a profound impact on the lives of CKD patients worldwide.